Translational cancer research
The translational cancer research area is a consortium of several strong research groups. The researchers' diverse and high-level expertise ranges from basic research at the molecular level to demanding clinical expertise. The research rests on modern research methods and extensive national and international networks. Research provides for a better understanding of the basic mechanisms, diagnostics and treatment of cancer – we bring personalised medicine to the clinic.
Cancer research at the University of Eastern Finland focuses especially on cellular-level genomics and epigenomics, extracellular matrix, cancer markers and clinical applications, environmentally induced cancer and its mechanisms, the use of diverse imaging methods and bioinformatics expertise, and metabolism, transfer, novel administration methods and modelling of cancer drugs. The foundations of translational cancer research rest on clinical sample series which have undergone quality assurance as well as on the related knowledge of diagnostics, epidemiology and treatment.
- The role of extracellular hyaluronan on the development and spreading of cutaneous melanoma
- Mobilization regimen affects the composition of blood grafts and post-transplant recovery in autologous stem cell transplantations
- Celebrating hyaluronan research – new treatment can improve cancer prognosis
- Scientists identify 72 new genetic variants contributing to breast cancer risk
- UEF joins national biobank cooperative
- Abnormal early blood cell differentiation predisposes to childhood leukemia
- Disturbances in blood cell gene transcription may lead to leukemia
- Academy of Finland grants funding for Biobank of Eastern Finland
- Low breast density in mammography worsens breast cancer prognosis
INCREASINGLY PRECISE TREATMENT FOR CANCER
“The objective is to identify the key factors contributing to the risk of cancer, to improve cancer diagnostics, and to develop increasingly personalised and more effective treatments," says ProfessorVeli-Matti Kosma.